Celator Pharmaceuticals Inc·4

Mar 17, 4:59 PM ET

Celator Pharmaceuticals Inc 4

4 · Celator Pharmaceuticals Inc · Filed Mar 17, 2016

Insider Transaction Report

Form 4
Period: 2016-03-15
Mayer Lawrence David
President and Head of Research
Transactions
  • Tax Payment

    Common Stock

    2016-03-15$8.94/sh12,081$108,004107,515 total
  • Exercise/Conversion

    Common Stock

    2016-03-15$2.25/sh+48,002$108,005119,596 total
  • Exercise/Conversion

    Stock Option, Right to Buy

    2016-03-1548,0020 total
    Exercise: $2.25Exp: 2016-03-22Common Stock (48,002 underlying)
Holdings
  • Common Stock

    (indirect: By Spouse)
    7,468
  • Common Stock

    (indirect: By Trust)
    3,631
Footnotes (1)
  • [F1]These options are fully exercisable.

Documents

1 file
  • 4
    v434636_4.xmlPrimary

    FORM 4